Aunan Greg D 4

What Happened Greg D. Aunan, Chief Accounting Officer of NeoGenomics, received equity awards on March 1, 2026: 36,825 stock options and 22,889 restricted stock units (RSUs). Both awards were granted at $0 acquisition price (typical for compensation grants) and are recorded as derivative/award transactions rather than open-market purchases or sales.

Key Details

• Transaction date: March 1, 2026; Form filed March 3, 2026 (timely filing).
• Grants: 36,825 stock options; 22,889 RSUs. Reported acquisition price: $0.00 (award).
• Vesting for the March 1, 2026 awards: vest ratably over the first three anniversaries of the grant date (footnotes F1–F2).
• Additional prior awards to Mr. Aunan (listed in the filing):
  • 5/1/2023: 28,662 stock options (vest ratably over 4 years) (F4)
  • 5/2/2024: 26,978 stock options (vest ratably over 3 years) (F5)
  • 5/2/2024: 16,117 RSUs (vest ratably over 3 years) (F6)
  • 2/21/2025: 31,163 stock options (vest ratably over 3 years) (F7)
  • 2/21/2025: 18,971 RSUs (vest ratably over 3 years) (F8)
• Once RSUs convert to shares upon vesting, the shares are not subject to expiration (F3).
• Shares owned after the reported grants are not specified in the provided filing excerpt.

Context These entries are standard equity compensation grants to an executive (an "award" — filing code A). Grants do not involve an immediate cash outlay by the insider and are different from purchases (which can signal a personal investment). Vesting schedules mean the awards convert to actual shares over time; until vested, the options/RSUs are subject to the company’s award terms.